These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22740347)

  • 1. Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer.
    Johung K; Rewari A; Wu H; Judson B; Contessa JN; Haffty BG; Decker RH
    Head Neck; 2013 Jun; 35(6):852-7. PubMed ID: 22740347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
    Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.
    Bišof V; Jakovčević A; Seiwerth S; Rakušić Z; Gašparov S
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):187-94. PubMed ID: 23011763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
    Goyal S; Parikh RR; Green C; Schiff D; Moran MS; Yang Q; Haffty BG
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):679-84. PubMed ID: 19464815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
    Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
    Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
    J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.
    Hirakawa H; Ikegami T; Azechi S; Agena S; Uezato J; Kinjyo H; Yamashita Y; Tanaka K; Kondo S; Maeda H; Suzuki M; Gahana A
    Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):601-610. PubMed ID: 31749055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
    Mehra R; Zhu F; Yang DH; Cai KQ; Weaver J; Singh MK; Nikonova AS; Golemis EA; Flieder DB; Cooper HS; Lango M; Ridge JA; Burtness B
    Clin Cancer Res; 2013 Dec; 19(23):6633-43. PubMed ID: 24088734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
    Hasegawa K; Kato R; Torii Y; Ichikawa R; Oe S; Udagawa Y
    Int J Gynecol Cancer; 2011 Nov; 21(8):1479-85. PubMed ID: 21720251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
    Hao D; Lau HY; Eliasziw M; Box A; Diaz R; Klimowicz AC; Shin B; Lees-Miller SP; Magliocco AM
    Head Neck; 2012 Jun; 34(6):785-91. PubMed ID: 22127805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.
    Dorff TB; Schuckman AK; Schwartz R; Rashad S; Bulbul A; Cai J; Pinski J; Ma Y; Danenberg K; Skinner E; Quinn DI
    Clin Genitourin Cancer; 2016 Oct; 14(5):450-456.e1. PubMed ID: 26935231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
    Jun HJ; Ahn MJ; Kim HS; Yi SY; Han J; Lee SK; Ahn YC; Jeong HS; Son YI; Baek JH; Park K
    Br J Cancer; 2008 Jul; 99(1):167-72. PubMed ID: 18594541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.